Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3194701 | Clinics in Dermatology | 2012 | 14 Pages |
Abstract
Bullous pemphigoid (BP) constitutes the most frequent autoimmune subepidermal blistering disease. It is associated with autoantibodies directed against the BP antigens 180 (BP180, BPAG2) and BP230 (BPAG1-e). The pathogenicity of anti-BP180 antibodies has been convincingly demonstrated in animal models. The clinical features of BP are extremely polymorphous. The diagnosis of BP critically relies on immunopathologic findings. The recent development of novel enzyme-linked immunosorbent assays has allowed the detection of circulating autoantibodies with relatively high sensitivity and specificity. Although potent topical steroids have emerged in the past decade as first-line treatment of BP, management of the disease may be challenging.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Giovanni Di Zenzo, Rocco della Torre, Giovanna Zambruno, Luca Borradori,